A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode

NCT00378092 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Oral risperidone
DRUG: Risperidone Long-Acting Injection (RLAI)
DRUG: Risperidone Long-Acting Injection (RLAI)

Sponsor

Janssen Cilag N.V./S.A.